دورية أكاديمية
Brief Report: Safety and Antitumor Activity of Durvalumab Plus Tremelimumab in Programmed Cell Death-(Ligand)1–Monotherapy Pretreated, Advanced NSCLC: Results From a Phase 1b Clinical Trial.
العنوان: | Brief Report: Safety and Antitumor Activity of Durvalumab Plus Tremelimumab in Programmed Cell Death-(Ligand)1–Monotherapy Pretreated, Advanced NSCLC: Results From a Phase 1b Clinical Trial. |
---|---|
المؤلفون: | Garon, Edward B., Spira, Alexander I., Goldberg, Sarah B., Chaft, Jamie E., Papadimitrakopoulou, Vassiliki, Cascone, Tina, Antonia, Scott J., Brahmer, Julie R., Camidge, D. Ross, Powderly, John D., Wozniak, Antoinette J., Felip, Enriqueta, Wu, Song, Ascierto, Maria L., Elgeioushi, Nairouz, Awad, Mark M. |
المصدر: | Journal of Thoracic Oncology; Aug2023, Vol. 18 Issue 8, p1094-1102, 9p |
قاعدة البيانات: | Complementary Index |
كن أول من يترك تعليقا!